Soleno Therapeutics Investors Urged to Lead Class Action Lawsuit Amid Allegations of Misleading Safety Data

Legal Action Against Soleno Therapeutics: A Class Action Guide

Soleno Therapeutics, Inc. (NASDAQ: SLNO) has been under scrutiny as a national law firm, Hagens Berman, calls attention to a potential class action lawsuit for shareholders who faced significant losses. The firm is reminding investors of the key deadline on May 5, 2026, to apply to become lead plaintiffs in a lawsuit that alleges serious misrepresentations by Soleno concerning its safety protocols and product efficacy.

Background on Soleno Therapeutics and DCCR

Soleno specializes in developing treatments for rare genetic disorders, including Prader-Willi syndrome (PWS), and its flagship product, VYKAT™ XR (DCCR), has been marketed with assurances of safety and efficacy. However, a recent investigation has raised alarms regarding the accuracy of these claims.

Investors who acquired Soleno stock during the period from March 26, 2025, to November 4, 2025—the specified ‘Class Period’—and suffered financial losses are now being urged to step forward. The plaintiffs allege that Soleno failed to disclose significant safety risks associated with DCCR, primarily concerns regarding excess fluid retention and potential heart failure in pediatric patients treated with the drug.

Allegations of Misleading Information

The allegations extend beyond safety issues. Activist reports, particularly one from Scorpion Capital, have claimed that Soleno misrepresented the commercial viability of DCCR. The report highlighted discrepancies in the data obtained from a Phase 3 clinical trial supposedly overseen by a controversial physician whose integrity was called into question.

Moreover, the lawsuit claims that Soleno inflated the success metrics of its DCCR product launch, stating that figures representing market engagement were misleading and artificially manipulated, not reflective of actual market demand.

Impact of Recent Developments

The gravity of the situation escalated significantly when, on August 15, 2025, Scorpion Capital published a critical report detailing adverse reactions experienced by patients, which resulted in a steep decline of Soleno’s stock price. The consensus following this report indicated a growing skepticism among investors regarding the integrity of the company’s data and marketing practices.

Additionally, on November 4, 2025, Soleno’s disclosure of its third-quarter earnings exacerbated the situation, revealing downward adjustments in predicted patient starts for DCCR, leading to a dramatic 27% fall in stock value in a single trading day.

Next Steps for Investors

Hagens Berman has advised all affected shareholders to submit their losses ahead of the impending deadline, thereby increasing the chances for those seeking to lead the class action. Investors are encouraged to reach out and provide any pertinent information that could be valuable to the investigation.

With the prospect of recovery for affected investors, the opportunity to take a stand against what is seen as corporate negligence offers a path for accountability. Those possessing inside information regarding the company are additionally invited to explore their options under the SEC Whistleblower program, which could yield financial compensation for information leading to successful enforcement actions.

Conclusion

The unfolding situation surrounding Soleno Therapeutics raises significant concerns not only for shareholders but also for the broader implications for investor protection in the pharmaceutical industry. As the deadline approaches, affected individuals are advised to act promptly to safeguard their rights and interests. If you have experienced substantial losses related to your investment in Soleno, consider participating in this pivotal class action as the implications of the findings could lead to substantial recoveries. For more information regarding the lawsuit, potential participation, or any inquiries, investors should contact Reed Kathrein at Hagens Berman.

With growing scrutiny over safety practices and transparency, these developments serve as a crucial reminder of the importance of diligence in corporate governance and investor advocacy.